BCMA Bispecific Antibody Therapy for Post-BCMA CAR T-Cell Therapy Relapse (RECLAIM)

This is a single-center, single-arm, phase 2 study designed to evaluate the efficacy and safety of linvoseltamab in multiple myeloma (MM) patients who relapsed following BCMA CAR T-cell therapy, whether standard of care or investigational.

NCT Number	NCT07009899
Lead Sponsor	Medical College of Wisconsin
Conditions	Multiple Myeloma
Enrollment	34 participants
Start Date	2026-10-01
Primary Completion	2028-02-01 (estimated)
Study Completion	2029-02-01 (estimated)
Updated on ClinicalTrials.gov	2026-08-10